FDA
-
-
-
-
-
-
-
BMO Capital Reiterates Outperform Rating on Disc Medicine (IRON)
-
-
-
-
-
-
-
Jefferies Defends Disc Medicine (IRON): 'Overreaction to Article on IRON EPP Approvability Under CNPV'
-
-
-
-
-
-
-
Disc Medicine (IRON) PT Raised to $153 at Cantor Fitzgerald After FDA Priority Voucher Win
-
-
-
-
-
-
-
Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)
-
-
-
-
-
-
-
Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Disc Medicine (IRON) PT Raised to $118 at H.C. Wainwright
-
-
-
-
-
-
-
Jefferies Starts Disc Medicine (IRON) at Buy
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

